Navigation Links
Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL

days post last dose, Day 59 Table 4: ISIS 301012 Coadministered with Statins, Laboratory Findings. Number of patients with ALT elevations >/= 3xULN (maximal ALT observed = 211 IU/L). ALT Elevations Single(+) / Placebo 30 mg 100 mg 200 mg 300 mg 400 mg Consecutive(++) (n = 13) (n = 8) (n = 8) (n =16) (n = 8) (n = 8) Primary Endpoint (Day 1 to 59) 0 / 0 0 / 0 0 / 0 1 / 0 0 / 1 1 / 0 Primary Follow-up (Day 60 to 87) 0 / 0 0 / 0 0 / 0 0 / 1 0 / 0 0 / 0 Long term F/U (Day 88 to 199) 0 / 0 0 / 0 0 / 0 0 / 0 NA NA (+) Single = elevation that returned to below 3xULN by the next visit at least 7 days later (++) Consecutive = elevation that was observed in two measures at least 7 days apart Primary endpoint period was 30 days post last dose, Day 59 Primary follow-up period was from primary endpoint to 8 weeks post last dose NA = data not available, cohorts remain in follow-up Presentation Details Date: Monday, March 26, 2007 Session: 820: Clinical Trials of Lipid-Lowering Therapy (4:00 - 5:30 p.m. CT) Track: ACC.Vascular Disease, Hypertension, and Prevention Room: Auditorium B Presentation: 820-6 Time: 4:45 - 5:00 p.m. Speaker: Dr. John J.P. Kastelein Title: ISIS 301012, an Antisense Inhibitor of Apolipoprotein B, Produces Significant Additional Reduction of Low-Density Lipoprotein Cholesterol and Apolipoprotein B in Hypercholesterolemic Subjects on Statins Not Meeting Target More about Phase 2 Trials for ISIS 301012

Additional data from two studies evaluating ISIS 301012's safety and lipid lowering activity were presented at the ACC. This morning in an ora
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:7/27/2015)... 27, 2015  Array BioPharma Inc. (Nasdaq: ... the fourth quarter and full year of ... to discuss those results on Monday, August ... will lead the call.  Date:Monday, ... 507-2598Pass Code: 68380312 Webcast, including Replay and ...
(Date:7/27/2015)... July 27, 2015 As per the ... - Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... 7.96 billion in 2014, growing at a CAGR of 13.2% ... in 2021. The global bionics market is growing ... which is leading to paralysis or amputation of body parts. ...
(Date:7/27/2015)... , July 20, 2015 Research and ... the "Medical Device Regulation in Asia/Pacific Markets Seminar" ... that the European Medical Device market is well established, ... . China , together with other ... in the process of implementing, their own medical device ...
Breaking Medicine Technology:Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 2Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 3Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 4Medical Device Regulation in Asia/Pacific Markets Seminar: London, UK - 21st, 22nd of September 2015 2
... Advances and Expands Internal Pipeline as DARA Program Enters ... Development and New SARM Program is Added, PRINCETON, ... for the quarter and nine months ended,September 30, 2007, ... corporate milestones achieved since the beginning,of the quarter. ...
... Laboratories, Inc.,(NYSE: FRX ) today announced ... trial, published in the November 2007 issue ... that nebivolol,significantly reduced sitting diastolic and systolic ... with stage I-II hypertension.,The study also found ...
Cached Medicine Technology:Pharmacopeia Announces Third Quarter 2007 Financial Results 2Pharmacopeia Announces Third Quarter 2007 Financial Results 3Pharmacopeia Announces Third Quarter 2007 Financial Results 4Pharmacopeia Announces Third Quarter 2007 Financial Results 5Pharmacopeia Announces Third Quarter 2007 Financial Results 6Pharmacopeia Announces Third Quarter 2007 Financial Results 7Pharmacopeia Announces Third Quarter 2007 Financial Results 8Pharmacopeia Announces Third Quarter 2007 Financial Results 9Pharmacopeia Announces Third Quarter 2007 Financial Results 10Pharmacopeia Announces Third Quarter 2007 Financial Results 11UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension 2UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension 3
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... ... today, especially in wound center management. Earlier this year Wound Care Advantage ... education and training for WCA wound centers. Customized learning paths allow for ...
(Date:7/27/2015)... ... July 27, 2015 , ... In a piece published July ... of plastic surgery and explained why people should not shy away from their own ... excesses of the few and celebrate it for the modern wonder that it is.” ...
(Date:7/27/2015)... ... ... North Central Surgical Center Hospital will be holding twice-monthly joint wellness classes ... patients, along with their friends and family members, to attend. The classes take place ... 8 [Tue due to Labor Day], Oct 5, Nov 2, Dec 7) beginning at ...
(Date:7/27/2015)... ... ... A Harris County jury awarded a group of Texas and Canadian investors approximately ... on findings of fraud and violations of the Texas Securities Act. The verdict was ... 2010-09675; Jo Ann Schermerhorn, et al v. CenturyLink, Inc. and Robert Kubbernus, et al., ...
(Date:7/27/2015)... ... July 27, 2015 , ... ... To Reduce Hospital Readmissions." , The Centers for Medicare and Medicaid Services (CMS) ... as part of their penalty calculation. Known as the QualityNet Hospital-Specific Report (HSR), ...
Breaking Medicine News(10 mins):Health News:Wound Care Advantage Launches Luvo University An Online Hub For Wound Care Education and Training 2Health News:Wound Care Advantage Launches Luvo University An Online Hub For Wound Care Education and Training 3Health News:Recent Op-Ed Defending Plastic Surgery Highlights the Personal Side of Cosmetic Procedures, says Beverly Hills Physicians 2Health News:North Central Surgical Center Hospital to Hold Joint Wellness Classes 2Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 2Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 3Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 4Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 5Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 6Health News:BESLER Consulting Publishes E-book Focused on Reducing Hospital Readmissions 2
... On the eve of President Obama,s healthcare summit ... said today that expanding and updating Medicare to ... approach to achieving the goals and principles outlined ... Congress and budget proposal.While welcoming President Obama,s call ...
... University Baptist Medical Center, and colleagues, have identified a ... people with cystic fibrosis, a lethal genetic condition. The ... treatment, researchers say. , The study appeared online last ... . It is the first published study to search ...
... IDIX ) announced today that management will present ... Conference on Tuesday, March 10th at 1:30 p.m. ET at ... Company 29th Annual Healthcare Conference on Tuesday , March ... Marriott Copley Place.The live and archived webcasts of the presentations ...
... WXYZ is proud to announce that ... Nielsen , will now be seen exclusively on Channel ... 15 years Peter Nielsen has hosted the nationally syndicated ... author of numerous books and videos on health and fitness and is ...
... Genaera Corporation (Nasdaq: GENR ) today announced its financial ... net loss for the year ended December 31, 2008 was $16.0 ... a net loss of $15.7 million, or $(0.90) per share basic ... loss for the quarter ended December 31, 2008 was $3.6 million, ...
... percent increased chance of death, rehospitalization , , TUESDAY, March ... blood thinner Plavix, plus a proton pump inhibitor such ... of death or another heart attack, a new study ... help reduce the risk of another heart attack after ...
Cached Medicine News:Health News:Nation's RNs on the Healthcare Summit: Insurance-Based Reform Will Fail, and Undermine Public Trust, Only Medicare for All Can Achieve Administration's Goals 2Health News:Nation's RNs on the Healthcare Summit: Insurance-Based Reform Will Fail, and Undermine Public Trust, Only Medicare for All Can Achieve Administration's Goals 3Health News:Scientists find gene that modifies severity of cystic fibrosis lung disease 2Health News:Scientists find gene that modifies severity of cystic fibrosis lung disease 3Health News:Peter Nielsen Has a New Home on WXYZ-TV! 2Health News:Genaera Corporation Announces 2008 Financial Results 2Health News:Genaera Corporation Announces 2008 Financial Results 3Health News:Genaera Corporation Announces 2008 Financial Results 4Health News:Genaera Corporation Announces 2008 Financial Results 5Health News:Blood Thinner, Heartburn Drugs May Be Risky After Heart Attack 2Health News:Blood Thinner, Heartburn Drugs May Be Risky After Heart Attack 3
CHEMICON's Advanced Tissue Arrayer with patent-pending technology allows you to create customized arrays of multiple tissu specimens on a single slide, saving time and money....
CO2 gas object holder and knife freezer for the 8000 Series Sliding Microtome...
Tilt Adapter for the 8000 Sliding Microtome to allow for orientation of the specimen....
... 5040 microtome is of rotary retracting, self-lubricating design ... cutting arm. Its robust construction makes it accurate ... hinges means that all lateral motion is controlled ... be experienced in other, lesser designs which can ...
Medicine Products: